1. EGFR inhibitors
2. ALK inhibitors
3. Less common molecular targets
4. Role of KRAS inhibitors and evidence for sotorasib
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
1. de Langen AJ et al. The Lancet. 2023;401(10378):733-746. doi:10.1016/S0140-6736(23)00221-0
2. Wolf J et al. NEJM. 2020;383(10):944-957. doi:10.1056/NEJMOA2002787/
3. Felip E et al. Annals of Oncology. 2021;32(5):620-630. doi:10.1016/j.annonc.2021.02.012
4. Cho BC et al. J Thorac Oncol. 2017;12(9):1357-1367. doi:10.1016/J.JTHO.2017.07.005
5. Peters S et al. NEJM. 2017;377(9):829-838. doi:10.1056/NEJMOA1704795/
6. Solomon BJ et al. JCO. 2018;36(22):2251-2258. doi:10.1200/JCO.2017.77.4794
7. Solomon BJ et al. NEJM. 2014;371(23):2167-2177. doi:10.1056/NEJMOA1408440
8. Yang JCH et al. Lancet Oncol. 2015;16(2):141-151. doi:10.1016/S1470-2045(14)71173-8
9. Soria JC et al. NEJM. 2018;378(2):113-125. doi:10.1056/NEJMOA1713137/
10. Ramalingam SS et al. NEJM. 2020;382(1):41-50. doi:10.1056/NEJMOA1913662/
11. Zhang SS et al. Lung Cancer: Targets and Therapy. 2023;14:27. doi:10.2147/LCTT.S403461
12. Olivier T et al. Transl Oncol. 2023;28:101591. doi:10.1016/J.TRANON.2022.101591
13. Papadimitrakopoulou VA, et al. Ann Oncol. 2020;31(11):1536-1544. doi:10.1016/J.ANNONC.2020.08.2100
14. Fukuoka M et al. J Clin Oncol. 2011;29(21):2866-2874. doi:10.1200/JCO.2010.33.4235
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
1. EGFR inhibitors
2. ALK inhibitors
3. Less common molecular targets
4. Role of KRAS inhibitors and evidence for sotorasib
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
1. de Langen AJ et al. The Lancet. 2023;401(10378):733-746. doi:10.1016/S0140-6736(23)00221-0
2. Wolf J et al. NEJM. 2020;383(10):944-957. doi:10.1056/NEJMOA2002787/
3. Felip E et al. Annals of Oncology. 2021;32(5):620-630. doi:10.1016/j.annonc.2021.02.012
4. Cho BC et al. J Thorac Oncol. 2017;12(9):1357-1367. doi:10.1016/J.JTHO.2017.07.005
5. Peters S et al. NEJM. 2017;377(9):829-838. doi:10.1056/NEJMOA1704795/
6. Solomon BJ et al. JCO. 2018;36(22):2251-2258. doi:10.1200/JCO.2017.77.4794
7. Solomon BJ et al. NEJM. 2014;371(23):2167-2177. doi:10.1056/NEJMOA1408440
8. Yang JCH et al. Lancet Oncol. 2015;16(2):141-151. doi:10.1016/S1470-2045(14)71173-8
9. Soria JC et al. NEJM. 2018;378(2):113-125. doi:10.1056/NEJMOA1713137/
10. Ramalingam SS et al. NEJM. 2020;382(1):41-50. doi:10.1056/NEJMOA1913662/
11. Zhang SS et al. Lung Cancer: Targets and Therapy. 2023;14:27. doi:10.2147/LCTT.S403461
12. Olivier T et al. Transl Oncol. 2023;28:101591. doi:10.1016/J.TRANON.2022.101591
13. Papadimitrakopoulou VA, et al. Ann Oncol. 2020;31(11):1536-1544. doi:10.1016/J.ANNONC.2020.08.2100
14. Fukuoka M et al. J Clin Oncol. 2011;29(21):2866-2874. doi:10.1200/JCO.2010.33.4235
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology